Skip to main content
logo
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.955
+0.055 (2.89%)
Aug 5, 2026, 10:25 AM EDT - Market open

Allogene Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--0.020.10.16114.09
Revenue Growth
---76.84%-39.10%-99.86%-
Gross Profit
--0.020.10.16114.09
Operating Income
-190.22-209.32-273.2-327.74-335.54-180.19
Net Income
-173.76-190.89-257.59-327.27-340.41-182.05
Earnings Per Share
-0.77-0.87-1.32-2.09-2.38-1.34
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
266.89250.21292.48448.7517.32457.3
Total Debt
72.6375.0583.2588.3595.1269.93
Net Cash (Debt)
194.25175.17209.23360.35422.2387.37
Net Cash Growth
-2.26%-16.28%-41.94%-14.65%8.99%-50.15%
Net Cash Per Share
0.860.791.072.302.952.85

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-109.23-149.25-200.3-237.73-220.52-184.81
Capital Expenditures
-0.3-0.39-0.69-1.52-5.19-21.45
Free Cash Flow
-109.53-149.63-200.99-239.25-225.71-206.26
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---1241810.00%-344986.00%-215087.00%-157.94%
Pretax Margin
---1168850.00%-344489.47%-218214.10%-159.57%
Profit Margin
---1170860.00%-344489.00%-218214.00%-159.57%
FCF Margin
---913609.00%-251841.00%-144686.00%-180.79%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
--20545.805698.335823.8318.65